This inventor holds 2 USPTO granted patents. Top assignees: Lek Pharmaceuticals D.d., University of Ljubljana, Faculty of Pharmacy. Active years: 2007-2009.
Company Filing History:
2 out of 107 
1 out of 2 Years Active: 2007-2009
Title: Mojca Stegnar: Innovator in Thrombin Inhibition
Introduction
Mojca Stegnar is a notable inventor based in Ljubljana, Slovenia. She has made significant contributions to the field of pharmaceuticals, particularly in the development of thrombin inhibitors. With a total of 2 patents, her work has the potential to impact medical treatments significantly.
Latest Patents
Mojca Stegnar's latest patents include innovative compounds that serve as thrombin inhibitors. The first patent describes novel thrombin inhibitors of the formula I and pharmaceutically acceptable salts thereof. These compounds are specifically designed to inhibit thrombin, which plays a crucial role in blood coagulation. The second patent focuses on amidinophenylalanine derivatives as thrombin inhibitors. This patent outlines a process for preparing these compounds and pharmaceutical compositions containing them, emphasizing their utility in thrombin inhibition.
Career Highlights
Throughout her career, Mojca has worked with prominent organizations such as Lek Pharmaceuticals D.d. and the University of Ljubljana, Faculty of Pharmacy. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Mojca has collaborated with several talented individuals, including Lucija Peterlin Marsic and Danijel Kikelj. These partnerships have enriched her research and development efforts, leading to innovative solutions in thrombin inhibition.
Conclusion
Mojca Stegnar's contributions to the field of thrombin inhibitors highlight her innovative spirit and dedication to advancing pharmaceutical science. Her patents represent significant advancements that could lead to improved medical treatments in the future.